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Abstract
This declaration, signed by an interdisciplinary task force of 234 experts from 83 different countries with
different backgrounds, highlights the threat posed by antimicrobial resistance and the need for appropriate use
of antibiotic agents and antifungal agents in hospitals worldwide especially focusing on surgical infections. As
such, it is our intent to raise awareness among healthcare workers and improve antimicrobial prescribing. To
facilitate its dissemination, the declaration was translated in different languages.
Antimicrobial resistance (AMR) has emerged as oneof the principal public health problems of the 21st
century. This has resulted in a public health crisis of inter-
national concern, which threatens the practice of modern
medicine, animal health, and food security. The substantial
problem of AMR is especially relevant to antibiotic resis-
tance (ABR), although antifungal resistance is increasing at
an alarming rate. Although the phenomenon of ABR can be
attributed to many factors, there is a well-established rela-
tionship between antibiotic prescribing practices and the
emergence of resistant bacteria.
This declaration, signed by an interdisciplinary task force of
234 experts from 83 different countries with different back-
grounds, highlights the threat posed by AMR and the need for
appropriate use of antibiotic agents and antifungal agents in
hospitals worldwide especially focusing on surgical infections.
This declaration is promoted by the Global Alliance for Infec-
tions in Surgery and the World Society of Emergency Surgery
(WSES). It is endorsed by the Surgical Infection Society (SIS),
the Surgical Infection Society Europe (SIS-E), the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) Study Group for Antimicrobial stewardship (ES-
GAP) and Study Group for Infections in Critically Ill Patients
(ESGCIP), the European Confederation of Medical Mycology
(ECMM), the World Alliance Against Antibiotic Resistance
(WAAR), the British Society for Antimicrobial Chemotherapy
(BSAC), the French Society of Anesthesia & Intensive Care
Medicine (SFAR), the Italian Society of Anesthesiology, An-
algesia, Resuscitation and Intensive Therapy (SIAARTI), the
South African Society of Clinical Microbiology (SASCM), the
Italian Society of Anti-Infective Therapy (SITA), and the Italian
Group for Antimicrobial Stewardship (GISA).
Antibiotic and Antifungal Resistance
Antibiotic resistance is one of the greatest threats to public
health, sustainable development, and security worldwide.
Its prevalence has increased alarmingly over the past de-
cades. In 2008, the acronym ‘‘ESKAPE’’ pathogens, which
refers to Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudo-
monas aeruginosa, and Enterobacter species was proposed to
highlight those pathogens about which ABR is of particular
concern and to emphasize which bacteria increasingly ‘‘es-
cape’’ the effects of antibiotics [1]. These organisms are in-
creasingly multi–drug- (MDR), extensive–drug- (XDR), and
pan–drug- resistant (PDR), and this process is accelerating
globally [2,3].
Although antibiotic-resistant infections are a widely rec-
ognized public health threat, less is known about the burden
of antifungal-resistant infections. The frequency of fungal
infections has increased in recent years, largely because of
the increasing size of the at-risk population, which includes
cancer patients, transplant recipients, patients with human
immunodeficiency virus infection, and other patients who
receive immunosuppressive therapy. In addition, they are
relatively common in critically ill patients and are associated
with considerable morbidity and death. In this regard, anti-
fungal resistance is becoming increasingly problematic,
particularly for Candida glabrata and Aspergillus fumigatus.
Recently, a new MDR species, C. auris, emerged causing
persistent multi-regional outbreaks. While some species of
Candida are inherently resistant to certain antifungal agents,
in others, acquired resistance occurs via selection of muta-
tions in existing genes, particularly in units with high
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antifungal consumption [4]. This can impact seriously the
outcomes of patients with invasive candidiasis. The problem
will likely continue to evolve unless greater attention is given
to measures to prevent and control the spread of resistant
Candida spp.
Combating resistance has become a top priority for global
policy makers and public health authorities. New mecha-
nisms of resistance continue to emerge and spread globally,
threatening our ability to manage common infections [5].
Antibacterial and antifungal use in animal and agricultural
industries aggravates selective pressure on microbes. A One
Health approach is required urgently. The burden of ABR is
difficult to quantify in some regions of the world, because
enhanced surveillance requires personnel, equipment, and
financial resources that are not always available [6]. The
worldwide impact of ABR is significant, however, in terms of
economic and patient outcomes, because of untreatable in-
fections or those necessitating antibiotic agents of last resort
(such as colistin) leading to increased length of hospital stay,
morbidity, death, and treatment cost.
Misuse and Overuse of Antibiotic Agents
Antibiotic agents can be lifesaving when treating patients
with bacterial infections but are often used inappropriately,
specifically when unnecessary or when administered for ex-
cessive durations or without consideration of pharmacoki-
netic principles. Large variations in antibiotic consumption
exist between countries, and while excessive use remains a
major problem in some areas of the world, elsewhere there is
lack of access to many antimicrobial agents. Antibiotic re-
sistance is a natural phenomenon that occurs as microbes
evolve. Human activities have accelerated the pace at which
bacteria develop and disseminate resistance, however. In-
appropriate use of antibiotic agents in humans and food-
producing animals, as well as poor infection prevention and
control (IPC) practices, contribute to the development and
spread of ABR.
Raising Awareness to Combat ABR
In line with a One Health approach, raising awareness of
ABR by education and dissemination of information to
stakeholders is an important factor in changing behaviors.
Efforts must be aimed at the general public, healthcare pro-
fessionals, food producing farmers, civil society organiza-
tions, and policy makers. An effective and cost-effective
strategy to reduce ABR should involve a multi-faceted ap-
proach aimed at optimizing antibiotic use, strengthening
surveillance and IPC, and improving patient and clinician
education regarding the appropriate use of antibiotic agents.
Although the current magnitude of the problem and its extent
in both the community and the hospital adds to the com-
plexity of any intervention, these are still necessary because
healthcare workers play a central role in preventing the
emergence and spread of resistance.
Improving Antibiotic Prescribing Behaviors
Appropriate use of antibiotic agents should be integral to
good clinical practice and standards of care [7,8]. Physicians
should be aware of their role and responsibility for main-
taining the effectiveness of current and future antibiotic
agents specifically by:
 Following locally developed customized antibiotic
guidelines and clinical pathways
 Supporting and enhancing IPC including correct hand
hygiene protocols
 Supporting and enhancing surveillance of ABR and
antibiotic consumption
 Prescribing and dispensing antibiotic agents only when
they are truly required
 Identifying and controlling the source of infection
 Prescribing and dispensing appropriate antibiotic
agents with adequate dosages—i.e., administration of
antibiotic agents according to pharmacokinetic-
pharmacodynamic (PK-PD) principles
 Re-assessing treatment when culture results are avail-
able
 Using the shortest duration of antibiotic agents based
on evidence
 Educating healthcare workers and staff how to use
antibiotic agents wisely
Antibiotic Stewardship Programs
Hospital-based programs dedicated to improving antibi-
otic use, commonly referred to as Antimicrobial Stewardship
Programs (ASPs), can both optimize the management of in-
fections and reduce adverse events associated with antibiotic
use [8,9]. Of note, a recent systematic review and meta-
analysis demonstrated that ASPs significantly reduce the
incidence of infections and colonization with antibiotic-
resistant bacteria and Clostridium difficile infections in hos-
pital inpatients [10]. Therefore, every hospital worldwide
should utilize existing resources to create an effective multi-
disciplinary team. The preferred means of improving anti-
biotic stewardship should involve a comprehensive program
that incorporates collaboration between various specialties
within a healthcare institution including infectious disease
specialists, hospital pharmacists, clinical pharmacologists,
administrators, epidemiologists, IPC specialists, microbiol-
ogists, surgeons, anesthesiologists, intensivists, and under-
utilized but pivotal stewardship team members—the surgical,
anesthetic, and intensive care nurses in our hospitals.
The ASP policies should be based on both international/
national antibiotic guidelines and tailored to local microbi-
ology and resistance patterns. Facility-specific treatment
recommendations, based on guidelines and local formulary
options promoted by the APS team, can guide clinicians in
antibiotic agent selection and duration for the most common
indications for antibiotic use. Standardizing a shared protocol
of antibiotic prophylaxis should represent the first step of any
ASP. Because physicians are responsible primarily for the
decision to use antibiotic agents, educating them and
changing the attitudes and knowledge that underlie their
prescribing behavior are crucial for improving antibiotic
prescription.
Education is fundamental to every ASP. A range of factors
such as diagnostic uncertainty, fear of clinical failure, time
pressure, or organizational contexts can complicate pre-
scribing decisions. Because of cognitive dissonance (recog-
nizing that an action is necessary but not implementing it),
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however, changing prescribing behavior is extremely chal-
lenging [11]. Efforts to improve educational programs are
thus required, and this should be complemented preferably by
active interventions such as prospective audits and feedback
to clinicians to stimulate further change [12]. It is also crucial
to incorporate fundamental ASP [13] and IPC principles in
under- and post-graduate training at medical faculties to
equip young physicians and other healthcare professionals
with the required confidence, skills, and expertise in the field
of antibiotic management.
The principles for appropriate prophylactic and therapeu-
tic use of antibiotic agents in surgical procedures are sum-
marized below.
Please, use antibiotics appropriately and play an active
role in combating antibiotic resistance. Join us now, as we
embark on this global cause, by pledging support for this
declaration and accepting responsibility for maintaining the
effectiveness and longevity of current and future antibiotic
agents.
Principles of Appropriate Antibiotic Prophylaxis
in Surgical Procedures
1. Antibiotic agents alone are unable to prevent surgical
site infections. Strategies to prevent surgical site in-
fections should always include attention to:
 IPC strategies including correct and compliant hand
hygiene practices
 Meticulous surgical techniques and minimization of
tissue trauma
 Hospital and operating room environments
 Instrument sterilization processes
 Peri-operative optimization of patient risk factors
 Peri-operative temperature, fluid, and oxygenation
management
 Targeted glycemic control
 Appropriate management of surgical wounds
2. Antibiotic prophylaxis should be administered for
operative procedures that have a high rate of post-
operative surgical site infection, or when foreign ma-
terials are implanted.
3. Antibiotic agents given as prophylaxis should be ef-
fective against the aerobic and anaerobic pathogens
most likely to contaminate the surgical site—i.e.,
gram-positive skin commensals or normal flora colo-
nizing the incised mucosae.
4. Antibiotic prophylaxis should be administered within
120 minutes before the incision. Administration of the
first dose of antibiotic agents beginning within 30 to 60
minutes before surgical incision, however, is re-
commended for most antibiotic agents (e.g., cefazolin),
to ensure adequate serum and tissue concentrations dur-
ing the period of potential contamination. Obese patients
‡120 kg require higher doses of antibiotic agents.
5. A single dose generally is sufficient. Additional anti-
biotic doses should be administered intra-operatively
for procedures >2–4 hours (typically where duration
exceeds two half-lives of the antibiotic) or with asso-
ciated significant blood loss (>1.5 L).
6. There is no evidence to support the use of post-
operative antibiotic prophylaxis.
7. Each institution is encouraged to develop guidelines
for proper surgical prophylaxis.
Principles of Appropriate Antibiotic Therapy
in Surgical Procedures
1. The source of infection should always be identified
and controlled as soon as possible.
2. Antibiotic empiric therapy should be initiated after a
treatable surgical infection has been recognized, be-
cause microbiologic data (culture and susceptibility
results) may not be available for up to 48–72 hours to
guide targeted therapy.
3. In critically ill patients, empiric broad-spectrum therapy
to cover the most likely pathogens should be initiated as
soon as possible after a surgical infection has been rec-
ognized. Empiric antimicrobial therapy should be nar-
rowed once culture and susceptibility results are available
and adequate clinical improvement is noted.
4. Empiric therapy should be chosen on the basis of local
epidemiology, individual patient risk factors for MDR
bacteria and Candida spp., clinical severity, and in-
fection source.
5. Specimens for microbiologic evaluation from the site
of infection are always recommended for patients with
hospital-acquired or with community-acquired infec-
tions at risk for resistant pathogens (e.g., previous
antimicrobial therapy, previous infection or coloniza-
tion with a MDR, XDR, and PDR pathogen) and in
critically ill patients. Blood cultures should be per-
formed before the administration of antibiotic agents
in critically ill patients.
6. The antibiotic dose should be optimized to ensure that
PK-PD targets are achieved. This involves prescribing
an adequate dose, according to the most appropriate
and right method and schedule to maximize the
probability of target attainment.
7. The appropriateness and need for antimicrobial treat-
ment should be re-assessed daily.
8. Once source control is established, short courses of
antibiotic therapy are as effective as longer courses
regardless of signs of inflammation.
 Intra-abdominal infection—four days are as effec-
tive as eight days in moderately ill patients [14]
 Blood stream infection—five to seven days are as
effective as seven to 21 days for most patients [15]
 Ventilator associated pneumonia—eight days are as
effective as 15 days [16,17].
9. Failure of antibiotic therapy in patients having con-
tinued evidence of active infection may require a re-
operation for a second source control intervention.
10. Biomarkers such as procalcitonin may be useful to
guide duration and cessation of antibiotic therapy in
critically ill patients.
11. Clinicians with advanced training and clinical expe-
rience in surgical infections should be included in the
care of patients with severe infections.
12. The IPC measures combined with ASPs should be
implemented in surgical departments. These inter-
ventions and programs require regular, systematic
monitoring to assess compliance and efficacy.
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13. Monitoring of antibiotic consumption should be im-
plemented and feedback provided to all ASP team
members regularly (e.g., every three to six months)
along with resistance surveillance data and outcome
measures.
The documents translated into French, Spanish, Portu-
guese, Chinese, Arabic, Russian, German, Japanese, Italian
and Greek are included in the Supplementary Material; see
online only supplementary material at www.liebertpub.com/sur.
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